Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Nasopharyngeal Carcinoma: early-phase trial registry

2 of 8 indexed Nasopharyngeal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Nasopharyngeal Carcinoma: 8 US clinical trials tracked, 2 recruiting.

Nasopharyngeal Carcinoma is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 2 of these trials.

Enrollment posture brief

Registry condition nasopharyngeal-carcinoma

OPEN 2 | RECR 25% | LATE 1 | EARLY 6 | RANK #2176 | SPON 2

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Nasopharyngeal Carcinoma (th…25%
Open-enrollment share among volume-matched conditions near Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nasopharyngeal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nasopharyngeal Carcinoma is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Nasopharyngeal Carcinoma research.

    Baylor College of Medicine accounts for 2 of 8 trials (25%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Nasopharyngeal Carcinoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 66 among the 8 trials that report a genuine target (sentinel values excluded). 6 of those (75%) plan for fewer than 100 participants.

  4. Nasopharyngeal Carcinoma research is mostly interventional.

    8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 21Phase 31

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1
Phase 3 1

Named interventions

Most-linked intervention names on Nasopharyngeal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Genetically modified CTLs Biological
1 trials
Epstein-Barr virus-specific adoptive T-cells immunotherapy Biological
1 trials
MABEL CTLs Biological
1 trials
PDR001 Drug
1 trials
DKY709 Drug
1 trials
Penpulimab Drug
1 trials
KFA115 Drug
1 trials
Radiographic Imaging Procedure
1 trials

US sites by state

Facility locations filed on Nasopharyngeal Carcinoma trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
California 3 trials
Texas 2 trials
Tennessee 2 trials
New York 2 trials
Pennsylvania 1 trials
Michigan 1 trials
Georgia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nasopharyngeal Carcinoma page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nasopharyngeal Carcinoma condition card totals 8 registered trials; most-linked intervention Genetically modified CTLs; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.